Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 63Breast Neoplasms 63Carcinoma, Non-Small-Cell Lung 39Triple Negative Breast Neoplasms 29Ovarian Neoplasms 25Fallopian Tube Neoplasms 22Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 16Stomach Neoplasms 11Neoplasm Metastasis 11Neoplasms 9Inflammatory Breast Neoplasms 9Breast Neoplasms, Male 9Melanoma 7Esophageal Neoplasms 7Cholangiocarcinoma 7Uterine Cervical Neoplasms 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Carcinoma, Ovarian Epithelial 6Pancreatic Adenocarcinoma 5Gallbladder Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Prostatic Neoplasms 3Peritoneal Neoplasms 3

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1HMPL-013 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastric Cancer Adenocarcinoma Metastatic × Taxes × Clear all
NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
68 enrolled
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡